Celgene Hits New 1-Year High at $96.44 (CELG)

Share on StockTwits

Celgene (NASDAQ:CELG) reached a new 52-week high on Tuesday , Analyst RN reports. The company traded as high as $96.44 and last traded at $94.99, with a volume of 2,081,546 shares traded. The stock had previously closed at $95.02.

CELG has been the subject of a number of recent research reports. Analysts at Deutsche Bank reiterated a “buy” rating on shares of Celgene in a research note on Tuesday, August 26th. Separately, analysts at RBC Capital raised their price target on shares of Celgene from $95.00 to $100.00 in a research note on Wednesday, August 6th. They now have an “outperform” rating on the stock. Finally, analysts at Zacks reiterated a “neutral” rating on shares of Celgene in a research note on Monday, July 28th. They now have a $92.00 price target on the stock. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and fourteen have given a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average target price of $97.00.

The stock has a 50-day moving average of $88.71 and a 200-day moving average of $80.34. The company has a market cap of $75.889 billion and a price-to-earnings ratio of 54.92.

Celgene (NASDAQ:CELG) last released its earnings data on Thursday, July 24th. The company reported $0.90 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.89 by $0.01. The company had revenue of $1.87 billion for the quarter, compared to the consensus estimate of $1.85 billion. During the same quarter in the prior year, the company posted $1.52 earnings per share. The company’s quarterly revenue was up 17.1% on a year-over-year basis. On average, analysts predict that Celgene will post $3.67 earnings per share for the current fiscal year.

Celgene Corporation is a global biopharmaceutical company engaged in the discovery, development and commercialization of therapies designed to treat cancer and immune-inflammatory related diseases.

Receive News & Ratings for Celgene Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Co and related companies with Analyst Ratings Network's FREE daily email newsletter.

Latest News

Pernod Forecasts Growth of Profit That Could Miss Estimates
Pernod Forecasts Growth of Profit That Could Miss Estimates
North Korea Frees Jeffrey Fowle Unexpectedly
North Korea Frees Jeffrey Fowle Unexpectedly
Staples Probing Possible Data Breach
Staples Probing Possible Data Breach
Shares of Adidas Jump on Reebok Possible Bid
Shares of Adidas Jump on Reebok Possible Bid
Michigan Pondering Ban on Tesla
Michigan Pondering Ban on Tesla
Train Drivers in Germany Call Two-Day Strike
Train Drivers in Germany Call Two-Day Strike


Leave a Reply

 
Advertisement
Advertisement
© 2006-2014 WKRB News.